Genmab A/S (NASDAQ:GMAB) Downgraded by ValuEngine

Genmab A/S (NASDAQ:GMAB) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday, ValuEngine reports.

GMAB has been the topic of a number of other reports. JPMorgan Chase & Co. raised shares of Genmab A/S from a “neutral” rating to an “overweight” rating and set a $23.00 price objective on the stock in a report on Thursday, September 12th. Royal Bank of Canada started coverage on shares of Genmab A/S in a report on Monday, August 12th. They set an “outperform” rating and a $23.00 price objective on the stock. Bank of America raised shares of Genmab A/S from a “neutral” rating to a “buy” rating in a report on Friday, September 13th. Morgan Stanley started coverage on shares of Genmab A/S in a report on Monday, August 12th. They set an “overweight” rating on the stock. Finally, HC Wainwright boosted their price objective on shares of Genmab A/S from $24.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Genmab A/S currently has a consensus rating of “Buy” and an average target price of $23.67.

Shares of GMAB stock opened at $22.01 on Wednesday. The business’s fifty day simple moving average is $20.73. The company has a debt-to-equity ratio of 0.01, a quick ratio of 18.72 and a current ratio of 18.72. Genmab A/S has a 12-month low of $13.64 and a 12-month high of $22.20.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, August 14th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $0.13. The business had revenue of $116.49 million for the quarter. On average, analysts predict that Genmab A/S will post 0.5 earnings per share for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in GMAB. Parametric Portfolio Associates LLC purchased a new stake in shares of Genmab A/S during the second quarter valued at $6,937,000. Oppenheimer Asset Management Inc. purchased a new stake in shares of Genmab A/S during the third quarter valued at $4,788,000. Synovus Financial Corp purchased a new stake in shares of Genmab A/S during the third quarter valued at $2,876,000. Envestnet Asset Management Inc. purchased a new stake in Genmab A/S in the third quarter valued at $2,698,000. Finally, Brinker Capital Inc. purchased a new stake in Genmab A/S in the third quarter valued at $988,000. 1.37% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).

See Also: Market Timing

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.